Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMNQG24)

Drug Name
Volociximab Drug Info
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMNQG24

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-5/beta-1 (ITGA5/B1) TTH4QIS ITA5_HUMAN-ITB1_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Integrin alpha-5/beta-1 (ITGA5/B1) DTT ITGA5-ITGB1 3.935 4.833 4.278 4.661
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Integrin alpha-5/beta-1 (ITGA5/B1) DTT ITGA5-ITGB1 2.88E-04 0.22 1.11
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00369395) A Study of Volociximab in Metastatic Melanoma. U.S. National Institutes of Health.
2 Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.